Enovis (ENOV)
NYSEHealth CareMedical - DevicesSnapshot 2026-11-04
$28.62+17.20%
Close 2026-11-05 · 1-day change
NYSEHealth CareMedical - DevicesSnapshot 2026-11-04
QuarterlyIQ Insights · ENOV
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -51.2% |
| Our one-year growth estimate | diamond | 5.9% |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
Usually moved in the same direction.
Price observations: 365 days
Most sensitive to the broad stock market.
Based on historical daily prices through 2026-11-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Growth built into the price is above our model estimate.
The price assumes 57.1 percentage points less one-year growth.
The one-year revenue growth assumption on Valuation.
Model as of 2026-11-04 · Compared with 29 industry peers · Company calendar date is not available
ENOV — earnings miss
Dated 2026-08-06
Results of Operations and Financial Condition. On August 6, 2026, the Company issued a press release reporting financial results for the second quarter ended July 3, 2026. A copy of the Company's press release is attached to this report as Exhibit 99.1 and is incorporated into
Why it matters: Enovis tied the deal to a 2027 margin hit, then said margins would improve again in 2028. New figures can test that plan.
Worry ifEnovis reports that its 2027 adjusted EBITDA margin fell by more than 100 basis points.
Less concerning ifEnovis reports 2027 dilution at or below 100 basis points, in line with its stated plan.
Why it matters: The health care sector is in a maturing phase, and growth has slowed. A return toward past growth highs would ease that concern.
Supportive ifSector data shows health care revenue growth rising back toward its prior highs from near 9%.
Worry ifSector data shows health care revenue growth staying near 9% or falling further.
Why it matters: Enovis has kept its $2.31–$2.37 billion revenue range. The next report tests that plan.
Supportive ifOn Nov. 5, Enovis keeps its $2.31–$2.37 billion 2026 revenue range and reports organic growth of 4% or more.
Worry ifOn Nov. 5, Enovis cuts the revenue range or reports organic growth below 4%.
Why it matters: P&R organic sales grew 3% in Q2, while reported sales fell 1%. Another drop in organic sales would weaken the growth picture.
Worry ifQ3 P&R organic sales decline year over year.
Less concerning ifQ3 P&R organic sales grow year over year, matching or beating Q2's 3% growth.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$239 on $10,000 · ±2.4% | How much price usually moves either way. |
| Bad day | $682 loss on $10,000 · 6.8% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $4,468 loss on $10,000 · 44.7% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: The $425–$435 million range calls for higher adjusted EBITDA than in 2025. Results will show if progress continues.
Supportive ifOn Nov. 5, Enovis keeps its $425–$435 million 2026 adjusted EBITDA range.
Worry ifOn Nov. 5, Enovis cuts the range below $425 million.